Key result
Current evidence-based management of systolic heart failure integrates new pharmacological and device therapies developed since the 2013 ACC/AHA guidelines.
This review provides an updated evidence-based approach to the management of systolic heart failure, incorporating new drugs and devices developed since the 2013 ACC/AHA guidelines.
Answers are grounded in this paper and cite their sources.
Supports updated systolic HF regimens with post-2013 therapies; extends 2013 guidelines via synthesized evidence.
Heart failure management is complex and constantly evolving. The American College of Cardiology and the American Heart Association (ACC/AHA) last issued evidence-based guidelines in 2013, and since then, new drugs and devices have been developed. This review presents an evidence-based approach to current heart failure management.
No takes yet. Share an insight, caveat, or question.
Okwuosa et al. (2016) studied this question. Current evidence-based management of systolic heart failure integrates new pharmacological and device therapies developed since the 2013 ACC/AHA guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: